CY1118873T1 - Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης - Google Patents
Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησηςInfo
- Publication number
- CY1118873T1 CY1118873T1 CY20171100221T CY171100221T CY1118873T1 CY 1118873 T1 CY1118873 T1 CY 1118873T1 CY 20171100221 T CY20171100221 T CY 20171100221T CY 171100221 T CY171100221 T CY 171100221T CY 1118873 T1 CY1118873 T1 CY 1118873T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical
- dosage form
- active ingredient
- solution administration
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Φέρεται στο προσκήνιο μια φαρμακευτικά αποδεκτή σύνθεση διαλυτοποίησης η οποία περιλαμβάνει (i) τουλάχιστον μία ένωση τοκοφερυλίου με χαρακτηριστική ομάδα πολυαλκυλενογλυκόλης και (ii) τουλάχιστον έναν μονοεστέρα λιπαρού οξέος με αλκυλενογλυκόλη ή μίγμα μονοεστέρα και διεστέρα λιπαρού οξέος με αλκυλενογλυκόλη. Η σύνθεση διαλυτοποίησης είναι χρήσιμη στη μεταποίηση προς μια φαρμακευτική δοσολογική μορφή η οποία περιλαμβάνει ένα μίγμα τήγματος τουλάχιστον ενός δραστικού συστατικού, τουλάχιστον ενός φαρμακευτικά αποδεκτού πολυμερούς. Το δραστικό συστατικό ή συστατικά μπορεί να έγκειται σε αναστολέα πρωτεάσης του HIV. Η σύνθεση διαλυτοποίησης ενισχύει τη βιοδιαθεσιμότητα του δραστικού συστατικού κατόπιν πρόσληψης από του στόματος.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83207406P | 2006-07-19 | 2006-07-19 | |
EP06015076A EP1880715A1 (en) | 2006-07-19 | 2006-07-19 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
EP07787658.9A EP2046298B1 (en) | 2006-07-19 | 2007-07-17 | Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition |
PCT/EP2007/057392 WO2008009689A1 (en) | 2006-07-19 | 2007-07-17 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118873T1 true CY1118873T1 (el) | 2018-01-10 |
Family
ID=37496705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100221T CY1118873T1 (el) | 2006-07-19 | 2017-02-17 | Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης |
Country Status (22)
Country | Link |
---|---|
US (2) | US9078921B2 (el) |
EP (2) | EP1880715A1 (el) |
JP (1) | JP5244102B2 (el) |
KR (1) | KR101424588B1 (el) |
CN (2) | CN101489537B (el) |
AU (1) | AU2007275177B2 (el) |
BR (1) | BRPI0715582A2 (el) |
CA (1) | CA2658395C (el) |
CY (1) | CY1118873T1 (el) |
DK (1) | DK2046298T3 (el) |
ES (1) | ES2612865T3 (el) |
HR (1) | HRP20170325T1 (el) |
HU (1) | HUE032551T2 (el) |
LT (1) | LT2046298T (el) |
MX (1) | MX2009000048A (el) |
PL (1) | PL2046298T3 (el) |
PT (1) | PT2046298T (el) |
RS (1) | RS55705B1 (el) |
RU (1) | RU2469708C2 (el) |
SI (1) | SI2046298T1 (el) |
WO (1) | WO2008009689A1 (el) |
ZA (1) | ZA200901110B (el) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5222550B2 (ja) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US8481554B2 (en) | 2009-05-27 | 2013-07-09 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
US20110034489A1 (en) * | 2009-07-31 | 2011-02-10 | Ranbaxy Laboratories Limited | Solid dosage forms of hiv protease inhibitors |
JP5779591B2 (ja) | 2009-12-22 | 2015-09-16 | アッヴィ・インコーポレイテッド | Abt−263カプセル剤 |
CA2792601C (en) * | 2010-03-10 | 2015-09-29 | Abbott Laboratories | Solid compositions of amorphous hcv inhibitors |
KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
UY33746A (es) | 2010-11-23 | 2012-06-29 | Abbott Lab | Método de tratamiento que usa inhibidores selectivos de bcl-2 |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2911651B1 (en) * | 2012-09-27 | 2016-06-22 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
EP2900219B1 (en) * | 2012-09-27 | 2016-07-06 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
US9744240B2 (en) | 2012-09-27 | 2017-08-29 | Basf Se | Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer |
US9789063B2 (en) | 2012-09-27 | 2017-10-17 | Basf Se | Storage-stable dust-free homogeneous particulate formulation |
KR102191562B1 (ko) * | 2012-11-07 | 2020-12-15 | 에스케이바이오팜 주식회사 | 난용성 약물의 고체분산체 및 이의 제조방법 |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6831704B2 (ja) * | 2014-06-18 | 2021-02-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 非イオン界面活性剤を含む新規の薬学的組成物 |
CN104523615B (zh) * | 2014-12-12 | 2017-07-04 | 常州康普药业有限公司 | 一种舒必利片及其制备方法 |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
RU2619840C1 (ru) * | 2016-09-21 | 2017-05-18 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция для лечения ВИЧ-инфекции |
RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
JP7365409B2 (ja) | 2018-06-28 | 2023-10-19 | エイアールエックス エルエルシー | 溶解性単位用量膜構造物を製造するための分配方法 |
KR102114550B1 (ko) * | 2018-07-10 | 2020-05-22 | 삼육대학교산학협력단 | 생리학적 체내 동태 연구 모델링을 이용한 약제학적 조성물의 제조 방법 |
CN111821309B (zh) * | 2020-04-30 | 2021-08-24 | 深圳市新阳唯康科技有限公司 | 一种具有改良溶出速度的达芦那韦组合物 |
CN117338733B (zh) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
DE10046541A1 (de) * | 2000-09-19 | 2002-03-28 | Knoll Ag | Mechanisch stabile darreichungsformen, enthaltend Ubichinone |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
EP1706606A1 (en) * | 2003-10-08 | 2006-10-04 | ECS Holdings, Inc. | System containing oxygen enriched diesel particulate filter and method thereof |
US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
FR2861992B1 (fr) * | 2003-11-10 | 2007-07-20 | Sanofi Synthelabo | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
AU2004308712A1 (en) * | 2003-12-23 | 2005-07-14 | Tibotec Pharmaceuticals Ltd. | Self-microemulsifying drug delivery systems of a HIV protease inhibitor |
FR2866192B1 (fr) * | 2004-02-11 | 2006-04-28 | Johnson Controls Tech Co | Systeme et procede automatiques de reparation d'une carte electronique |
US7790190B2 (en) * | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
US7318503B2 (en) * | 2004-04-26 | 2008-01-15 | Akebono Corporation (North America) | Pad retaining clips |
EP2332538A1 (en) * | 2004-05-21 | 2011-06-15 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
EP1827416A1 (en) * | 2004-12-03 | 2007-09-05 | Abbott Laboratories | Pharmaceutical compositions |
-
2006
- 2006-07-19 EP EP06015076A patent/EP1880715A1/en not_active Withdrawn
-
2007
- 2007-07-17 PL PL07787658T patent/PL2046298T3/pl unknown
- 2007-07-17 LT LTEP07787658.9T patent/LT2046298T/lt unknown
- 2007-07-17 RU RU2009105479/15A patent/RU2469708C2/ru active
- 2007-07-17 PT PT77876589T patent/PT2046298T/pt unknown
- 2007-07-17 EP EP07787658.9A patent/EP2046298B1/en active Active
- 2007-07-17 CN CN2007800268668A patent/CN101489537B/zh active Active
- 2007-07-17 RS RS20170203A patent/RS55705B1/sr unknown
- 2007-07-17 SI SI200731895A patent/SI2046298T1/sl unknown
- 2007-07-17 JP JP2009519974A patent/JP5244102B2/ja active Active
- 2007-07-17 DK DK07787658.9T patent/DK2046298T3/en active
- 2007-07-17 ES ES07787658.9T patent/ES2612865T3/es active Active
- 2007-07-17 CA CA2658395A patent/CA2658395C/en not_active Expired - Fee Related
- 2007-07-17 HU HUE07787658A patent/HUE032551T2/en unknown
- 2007-07-17 KR KR1020087032146A patent/KR101424588B1/ko active IP Right Grant
- 2007-07-17 US US12/305,870 patent/US9078921B2/en not_active Expired - Fee Related
- 2007-07-17 CN CN201210270063.XA patent/CN103055316B/zh active Active
- 2007-07-17 WO PCT/EP2007/057392 patent/WO2008009689A1/en active Application Filing
- 2007-07-17 BR BRPI0715582-4A patent/BRPI0715582A2/pt not_active IP Right Cessation
- 2007-07-17 MX MX2009000048A patent/MX2009000048A/es active IP Right Grant
- 2007-07-17 AU AU2007275177A patent/AU2007275177B2/en not_active Ceased
-
2009
- 2009-02-17 ZA ZA2009/01110A patent/ZA200901110B/en unknown
-
2015
- 2015-07-14 US US14/799,430 patent/US9616130B2/en not_active Expired - Fee Related
-
2017
- 2017-02-17 CY CY20171100221T patent/CY1118873T1/el unknown
- 2017-02-28 HR HRP20170325TT patent/HRP20170325T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118873T1 (el) | Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης | |
CY1105795T1 (el) | Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων | |
CY1110261T1 (el) | Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα | |
CY1116688T1 (el) | Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων | |
CY1119651T1 (el) | Στερεη φαρμακευτικη μορφη δοσολογιας περιλαμβανουσα στερεη διασπορα αναστολεα πρωτεασης hiv | |
CY1115386T1 (el) | Συνδυασμος αζελαστινης και μομεταζονης | |
CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
ATE398997T1 (de) | Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln | |
ECSP034913A (es) | Composiciones farmacéuticas que comprenden fármacos de solubilidad baja y/o sensibles a ácidos, y polimeros ácidos neutralizados | |
CY1112811T1 (el) | Απο το στοματος μορφη δοσολογιας που περιεχει αναστολεα ρdε 4 ως δραστικο συστατικο και πολυβινυλοπυρρολιδονη ως εκδοχο | |
CY1105237T1 (el) | Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir | |
DE60325354D1 (de) | Topisch anwendbare pharmazeutische zubereitung | |
DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
BRPI0506889A (pt) | derivados de benzimidazol | |
NZ581589A (en) | Solubilized sterile injectable formulation of docetaxel without Tween 80 | |
AR077338A1 (es) | Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion. | |
CY1111442T1 (el) | Ενωσεις πιπεριδινης και χρησεις αυτων | |
ATE359777T1 (de) | Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate | |
BRPI0514724A (pt) | inibidores da enzima hiv integrase | |
CY1120418T1 (el) | Φαρμακευτικη συνθεση και γαληνικη μορφη με βαση τη δρονεδαρονη και διαδικασια για την παρασκευη της | |
AR032642A1 (es) | Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral. | |
UY28057A1 (es) | Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos | |
BRPI0418294A (pt) | composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes | |
NZ603872A (en) | Oral dosage forms of bendamustine | |
UY27018A1 (es) | Derivados de la pirimidina |